

Spectron mrc announces commercial availability of GMP grade Non- Carrier-added Lutetium-177 Radioisotope for US market.

South Bend, IN June 19, 2018 – Under an exclusive arrangement with **Global Morpho Pharma SAS**, Spectron mrc a South Bend Indiana radiopharmaceutical manufacturer, today announced launching of a non- carrier added (n.c.a) Lutetium(¹⁷⁷Lu), for US market.

Non-carrier added (n.c.a) Lutetium(¹⁷⁷Lu), is an isotope used for therapeutic purposes. Currently multiple pharmaceutical companies are developing Lutetium(¹⁷⁷Lu) labelled therapies in the area of prostate cancer, kidney cancer, NET and pancreatic cancer. Demand for Lutetium(¹⁷⁷Lu) is expected to grow in the coming years exponentially. “We are pleased to have made a strategic decision to invest in the technology to develop Non-carrier added (n.c.a) Lutetium(¹⁷⁷Lu). Our South Bend Indiana facility offers a strategic location for global distribution” said Anwer Rizvi CEO of Spectron mrc, “we are ready to support clinical supply of ¹⁷⁷Lu for the various clinical trials in US and Europe”.

“Spectron has been an innovator in the development of various radiopharmaceutical technologies, including but not limited to Copper-64, Zirconium-89 and Iodine-124. Spectron is also offering these Radioisotopes to its commercial partners”, said Anwer Rizvi. “The therapeutic radioisotopes are key to our success as they offer a significant market opportunity globally. Spectron mrc and Global Morpho Pharma SAS will be present during the SNMMI congress in Philadelphia, PA, June 23 to 25, 2018 at booth #17.

About Spectron mrc

Spectron mrc (www.spectronmrc.com) is a committed partner in molecular imaging, offering a global distribution of the most advanced Radiopharmaceuticals. We offer the most reliable supply of novel research and clinical radionuclides with contract manufacturing services so that together we can make a difference in the lives of patients. Contact us to learn how our advanced radionuclides can help build your diagnostic and therapeutic supply chain needs.

About Global Morpho Pharma SAS

Global Morpho Pharma SAS (www.morphopharma.com) is a recently founded French radiopharmaceutical company aiming at providing to the major markets access to high quality radionuclides for medical applications from alternative sources. For the time being Morpho is concentrating on the supply of n.c.a. Lutetium-177 and Actinium-225, which will become available within the next months as pharmaceutical grade radionuclides.